Financials data is unavailable for this security.
View more
Year on year Divi's Laboratories Ltd 's net income deteriorated -12.25% from 18.23bn to 16.00bn despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
| Gross margin | 59.76% |
|---|---|
| Net profit margin | 20.45% |
| Operating margin | 23.73% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Divi's Laboratories Ltd increased its cash reserves by 113.53%, or 1.93bn. The company earned 12.61bn from its operations for a Cash Flow Margin of 16.07%. In addition the company used 2.69bn on investing activities and also paid 7.99bn in financing cash flows.
| Cash flow per share | 77.45 |
|---|---|
| Price/Cash flow per share | 70.40 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -12.25%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.80% |
|---|---|
| Div growth rate (5 year) | 13.40% |
| Payout ratio (TTM) | 47.55% |
| EPS growth(5 years) | 3.41 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 13.29 |
More ▼
